Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NASDAQ: NTLA) is a biotechnology company focused on developing CRISPR/Cas9-based genome editing therapies. Today, the stock experienced a strong bearish movement.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.1% on Mar 31, 2025 16:15

• The bearish movement in NTLA's stock could be attributed to the multiple class action lawsuits filed by law firms on behalf of investors, indicating potential legal challenges and uncertainties surrounding the company.
• The investigations and deadlines mentioned in recent communications may have raised concerns among investors about the financial implications and legal risks associated with holding NTLA shares, leading to a sell-off.
• Despite the positive news of NTLA's genome-editing therapy receiving FDA's RMAT tag for a new indication, the legal troubles seem to have overshadowed this development, causing a negative impact on the stock price.
• Investors might be cautious about the company's future performance and regulatory hurdles, reflecting in the downward movement of NTLA's stock.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Intellia Therapeutics ( NASDAQ:NTLA )

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options

https://www.benzinga.com/pressreleases/25/03/g44552060/deadline-alert-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-intellia-therapeuti

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. ( NTLA ) Shareholders

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders ...

https://markets.businessinsider.com/news/stocks/levi-korsinsky-announces-the-filing-of-a-securities-class-action-on-behalf-of-intellia-therapeutics-inc-ntla-shareholders-1034528515

Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion. - Intellia Therapeutics ( NASDAQ:NTLA )

Investors can contact the law firm at no cost to learn more about recovering their losses

https://www.benzinga.com/pressreleases/25/03/g44527821/intellia-therapeutics-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-apr

Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. ( NTLA ) of a Class Action Lawsuit and an Upcoming Deadline - Intellia Therapeutics ( NASDAQ:NTLA )

NEW YORK, March 27, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ( "Intellia" or the "Company" ) NTLA of a class action securities lawsuit.

https://www.benzinga.com/pressreleases/25/03/g44519707/levi-korsinsky-notifies-shareholders-of-intellia-therapeutics-inc-ntla-of-a-class-action-lawsuit-a

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.

https://www.zacks.com/stock/news/2436332/ntla-genome-editing-therapy-gets-fdas-rmat-tag-for-new-indication

Trending Today

Lido DAO ($LDO) Crypto Forecast: Up 5.2% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.0% Today

Filecoin ($FIL) Crypto Forecast: Up 5.2% Today

Pepe ($PEPE) Crypto Forecast: Up 5.4% Today

Toncoin ($TON) Crypto Forecast: Up 5.3% Today

Curve DAO Token ($CRV) Crypto Forecast: Up 5.2% Today

NEO ($NEO) Crypto Forecast: Down 12.1% Today

Cassava Sciences, Inc. ($SAVA) Stock Forecast: Down 5.2% Today

Discover Financial Services ($DFS) Stock Forecast: Up 5.0% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 5.0% Today

Intellia Therapeutics, Inc. Price History

04.02.2025 - NTLA Stock was down 10.6%

• NTLA's stock experienced a bearish movement possibly due to the looming class action securities lawsuit against the company, creating uncertainty and negative sentiment among investors.
• Despite reporting better-than-expected Q4 results, the narrower loss and increased revenues might not have been enough to offset concerns surrounding the legal issues the company is facing.
• The reminders from law firms about class action lawsuits against NTLA and other companies could have added to the negative pressure on the stock, leading to the bearish movement.
• Investors may be cautious about the potential implications of the legal challenges on NTLA's future performance, contributing to the downward trend in the stock price.

05.02.2025 - NTLA Stock was up 8.5%

• Intellia Therapeutics reported better-than-expected fourth-quarter 2024 results, with a narrower loss than estimates and an increase in revenues year over year. This positive financial performance likely contributed to the bullish movement in the stock.
• The inducement grants awarded to eleven new employees may indicate the company's confidence in its future growth and development, which could have instilled optimism among investors.
• Despite facing a class action lawsuit deadline, the company's ability to surpass revenue estimates and deliver positive surprises in earnings for the quarter ended December 2024 could have boosted investor sentiment and led to the bullish market movement.

18.02.2025 - NTLA Stock was down 5.7%

• The bearish movement in NTLA could be attributed to the pending class action lawsuits and investigations by multiple law firms, leading to uncertainty and potential legal liabilities for the company.
• Investors may be concerned about the impact of these legal proceedings on Intellia's financial stability and future prospects, prompting them to sell off their positions in the stock.
• The selling pressure on NTLA could have been exacerbated by Cathie Wood's Ark Invest offloading its holdings in the company.

20.02.2025 - NTLA Stock was down 5.4%

• NTLA stock witnessed a significant downward trend.
• Notices from law firms and upcoming class action lawsuits against the company might have influenced the negative market sentiment.
• Investors seem worried about potential legal consequences and financial risks linked to ongoing legal inquiries and lawsuits, resulting in a sell-off of NTLA shares.
• The ambiguity concerning legal processes and approaching deadlines could be impacting the stock price, contributing to today's bearish movement.

26.02.2025 - NTLA Stock was down 5.0%

• Speculations around the FDA's RMAT designation for Nexiguran Ziclumeran may have initially raised investors' expectations, potentially triggering profit-taking once the news was fully incorporated into the stock value.
• Ongoing shareholder investigations and lawsuits may have fostered uncertainty and negative sentiment towards the company, prompting some investors to liquidate their holdings.
• With the lead plaintiff deadline on the horizon, investors could be apprehensive about potential legal repercussions, likely contributing to the stock's bearish performance.

31.02.2025 - NTLA Stock was down 5.1%

• The bearish movement in NTLA's stock could be attributed to the multiple class action lawsuits filed by law firms on behalf of investors, indicating potential legal challenges and uncertainties surrounding the company.
• The investigations and deadlines mentioned in recent communications may have raised concerns among investors about the financial implications and legal risks associated with holding NTLA shares, leading to a sell-off.
• Despite the positive news of NTLA's genome-editing therapy receiving FDA's RMAT tag for a new indication, the legal troubles seem to have overshadowed this development, causing a negative impact on the stock price.
• Investors might be cautious about the company's future performance and regulatory hurdles, reflecting in the downward movement of NTLA's stock.

28.01.2025 - NTLA Stock was down 9.5%

• Despite reporting a narrower loss than estimates and an increase in revenues, NTLA experienced a bearish movement, indicating that the market may have had higher expectations.
• The reminder of class action lawsuits against Intellia Therapeutics might have created uncertainty among investors, leading to a sell-off of the stock.
• The market could be reacting to the overall sentiment towards gene editing companies, with investors possibly taking a cautious approach towards this sector.
• The strong bearish movement could also be influenced by profit-taking activities from traders who may have been holding the stock for a while, looking to capitalize on the recent positive news.

11.02.2025 - NTLA Stock was down 5.6%

• The bearish movement in NTLA's stock today could be attributed to the multiple class action lawsuits filed against the company by different law firms, which may have raised concerns among investors about potential legal liabilities and financial implications.
• The announcement of inducement grants to new employees might have also contributed to the negative sentiment, as it could signal increased expenses for the company at a time when investors are already cautious.
• The overall legal uncertainty surrounding NTLA, as highlighted by the shareholder reminders and class action suit deadlines, likely weighed on the stock and led to the bearish market movement today.

11.02.2025 - NTLA Stock was down 9.3%

• The bearish movement in Intellia Therapeutics' stock (NTLA) could be attributed to the multiple class action lawsuits being filed against the company.
• The negative investor sentiment following the reports of losses exceeding $50,000 and the reminder for shareholders to discuss their options with legal firms might have further contributed to the downward trend in the stock price.
• The inducement grants awarded to new employees under Nasdaq listing rules may not have been sufficient to offset the concerns raised by the ongoing legal actions, leading to increased selling pressure on the stock.
• Overall, the legal uncertainties surrounding Intellia Therapeutics seem to have overshadowed its innovative CRISPR-based therapies, impacting the market sentiment and driving the bearish movement in the stock.

25.02.2025 - NTLA Stock was down 5.5%

• NTLA stock's decline may be linked to current legal inquiries and lawsuits by shareholder representation, causing doubts and a negative outlook for the company.
• Investors might worry about the financial consequences of these legal battles on Intellia Therapeutics, resulting in stock sell-offs.
• Shareholders facing deadlines to join the lawsuits could heighten stock price pressures, casting uncertainty on the company's near-term prospects.

27.01.2025 - NTLA Stock was up 5.0%

• Q4 earnings and revenue of Intellia Therapeutics exceeded expectations, suggesting a positive financial performance and growth potential.
• The company's positive financial results, along with operational updates, likely contributed to an increase in investor confidence and the upward movement of the stock.
• Despite ongoing class action lawsuits related to securities law violations, investors seem to be emphasizing Intellia's recent achievements and financial stability, driving the bullish trend in NTLA stock.
• Investor optimism regarding Intellia's future in the gene editing sector appears to outweigh concerns about the legal challenges the company is currently confronting.

17.02.2025 - NTLA Stock was up 6.0%

• Investor confidence in NTLA seemed to drive the bullish movement, despite an ongoing securities class action investigation.
• The approaching deadline for investors to address their losses with legal firms possibly created a sense of urgency, leading to increased trading activity and a positive market response for NTLA.
• Speculations about Cathie Wood's Ark Invest adjusting their holdings and potentially increasing their stake in Intellia Therapeutics may have also contributed to the bullish movement, hinting at long-term growth prospects for the company.
• Despite ongoing investigations and alerts for investors who faced losses, a positive market sentiment persists for NTLA, pushing the stock price upwards.